5 reasons to use solifenacin Review article
Article Sidebar
Published:
Mar 31, 2024
Keywords:
urinary incontinence, overactive bladder, solifenacin
Main Article Content
Abstract
The paper discusses the most interesting aspects of the treatment of urinary incontinence and overactive bladder related to the use of solifenacin. Its mechanism of action, targeted selectivity and convenient dosing are discussed. It was emphasized that the therapy, especially against the background of competing active substances, significantly reduces side effects and improves the quality of life of the patients.
Article Details
How to Cite
Sapilak, B. J. (2024). 5 reasons to use solifenacin. Medycyna Faktow (J EBM), 17(1(62), 67-71. https://doi.org/10.24292/01.MF.0124.10
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as worldwide problem. Int J Gynecol Obstet. 2003; 82: 327-38.
2. Przydacz M, Golabek T, Dudek P et al. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study. Sci Rep. 2020; 10(1): 19819.
3. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006; 4(1): 14-24. http://doi.org/10.1016/j.amjopharm.2006.03.004.
4. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93(3): 303-10.
5. Chapple CR, Cardozo L, Steers WD et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006; 60(8): 959-66.
6. Surkont G, Wlazlak E, Suzin J. Solifenacyna – pierwsze doświadczenia w leczeniu pęcherza nadreaktywnego. Przeg Menopauzalny. 2006; 1: 43-46.
7. Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmakol. 2002; 335: 97-103.
8. Olcucu MT, Teke K, Yildirim K et al. Comparison effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study. Int Braz J Urol. 2020; 46(2):185-93.
9. Shim M, Kim JK, Bang WJ et al. Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study. Investig Clin Urol. 2020; 61(6): 600-6.
10. Haab F, Cardozo L, Chapple C et al. Solifenacin Study Group. Longterm open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005; 47: 376-84.
11. Kelleher CJ, Cardozo L, Chapple CR et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005; 95(1): 81-5.
12. Eisen SA, Miller DK, Woodward RS et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150(9): 1881-4.
13. Cardozo L, Amarenco G, Pushkar D et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, doubl-blind trial of solifenacin (SUNRISE). BJU Int. 2013; 111(5): 804-10.
14. Lee KS, Choo MS, Seo JT et al. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS). Health Qual Life Outcomes. 2015; 13: 89.
15. Gomes CM, Averbeck MA, Kovama M et al. Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil. Urology. 2020; 4: 1403-15.
16. Ali MU, Fong KNK, Kannan P et al. Measures of quality of life of people with neurogenic overactive bladder: A systematic review of psychometric properties. EJOG 2024; 292: 40-57.
17. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011; 2011: 834753.
18. He W, Huang G, Cui W et al. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol. 2023; 49(5): 535-63.
2. Przydacz M, Golabek T, Dudek P et al. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study. Sci Rep. 2020; 10(1): 19819.
3. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006; 4(1): 14-24. http://doi.org/10.1016/j.amjopharm.2006.03.004.
4. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93(3): 303-10.
5. Chapple CR, Cardozo L, Steers WD et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006; 60(8): 959-66.
6. Surkont G, Wlazlak E, Suzin J. Solifenacyna – pierwsze doświadczenia w leczeniu pęcherza nadreaktywnego. Przeg Menopauzalny. 2006; 1: 43-46.
7. Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmakol. 2002; 335: 97-103.
8. Olcucu MT, Teke K, Yildirim K et al. Comparison effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study. Int Braz J Urol. 2020; 46(2):185-93.
9. Shim M, Kim JK, Bang WJ et al. Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study. Investig Clin Urol. 2020; 61(6): 600-6.
10. Haab F, Cardozo L, Chapple C et al. Solifenacin Study Group. Longterm open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005; 47: 376-84.
11. Kelleher CJ, Cardozo L, Chapple CR et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005; 95(1): 81-5.
12. Eisen SA, Miller DK, Woodward RS et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150(9): 1881-4.
13. Cardozo L, Amarenco G, Pushkar D et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, doubl-blind trial of solifenacin (SUNRISE). BJU Int. 2013; 111(5): 804-10.
14. Lee KS, Choo MS, Seo JT et al. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS). Health Qual Life Outcomes. 2015; 13: 89.
15. Gomes CM, Averbeck MA, Kovama M et al. Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil. Urology. 2020; 4: 1403-15.
16. Ali MU, Fong KNK, Kannan P et al. Measures of quality of life of people with neurogenic overactive bladder: A systematic review of psychometric properties. EJOG 2024; 292: 40-57.
17. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011; 2011: 834753.
18. He W, Huang G, Cui W et al. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol. 2023; 49(5): 535-63.